We speculate that repurposing and further optimization of such “migraine drugs” (e.g., newly developed antibodies directed against CALCB or RAMP1)38 could perhaps offer novel therapeutic options for EwS patients in the future. This evidence concerns the gene CALCB and migraine disorder.